Cardiff Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $60.58M
- P/E (TTM)
- –
- Dividend yield
- –
About Cardiff Oncology
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a clinical-stage biotechnology firm that develops cancer therapies by targeting polo-like kinase 1 inhibition. It operates in a single business segment dedicated to oncology drug development. Its primary drug candidate is onvansertib, an oral small-molecule inhibitor tested in combination with standard medical treatments. The company focuses clinical programs on patients diagnosed with various malignancies, including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple-negative breast cancer, and chronic myelomonocytic leukemia.
All principal operations, executive decision-making functions, and assets are located in the United States. The company maintains a research laboratory in San Diego, California, to conduct biomarker testing and support drug development. Clinical trials take place across multiple medical centers in collaboration with external research partners, while third-party contractors handle drug manufacturing and distribution logistics.
Summary of the business section of Cardiff Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cardiff Oncology, Inc.
- Founded
- 2002
- Headquarters
- San Diego, CA
- Address
- 11055 Flintkote Avenue 92121
- Phone
- (858) 952-7570
- Website
- cardiffoncology.com
- Employees
- 31, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- CRDF
- Exchange
- Nasdaq
- IPO date
- Jul 27, 2004
- Shares outstanding
- 78M, Aug 6, 2026
- Public float
- $205.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, Mar 6, 2019; 1-for-6 reverse, Feb 20, 2019; 1-for-12 reverse, Aug 3, 2018; 1-for-12 reverse, Jun 4, 2018; 1-for-6 reverse, May 30, 2012; 1-for-6 reverse, May 29, 2012; 111-for-1, Jul 27, 2004
- SEC CIK
- 1213037
- CUSIP
- 14147L108
- ISIN
- US14147L1089
- LEI
- 549300AHOLZBHHYFWP04
- EIN
- 27-2004382
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mani Mohindru | Chief Executive Officer, Director | 59,067 |
| Mark Erlander | Chief Executive Officer, Director | 24,481 |
| Ajay Aggarwal | Chief Operating Officer | – |
| Tod Smeal | Chief Scientific Officer | – |
| Joshua B. Muntner | Chief Financial Officer | 500 |
| Brigitte Ute Lindsay | Chief Accounting Officer | 27,431 |
| Roger Sidhu | Chief Medical Officer | – |
| Fairooz Kabbinavar | Chief Medical Officer | – |
| James E. Levine | Chief Financial Officer | 127,716 |
| Gary W. Pace | Director | 3,389,337 |
| Renee P. Tannenbaum | Director | 20,000 |
| James O. Armitage | Director | 27,490 |
| Lale White | Director | 113,788 |
| Rodney S. Markin | Director | 31,060 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Erlander | $3.02M | $890.94K | $1.91M | $201 | – |
| FY2024 Mr. Erlander | $2.40M | $4.71M | $1.27M | $310 | – |
| FY2023 Mr. Erlander | $1.55M | $1.44M | $1.09M | $106 | – |
| FY2022 Mr. Erlander | $1.59M | $91.87K | $1.52M | $23 | – |
| FY2021 Mr. Erlander | $3.64M | -$1.40M | $2.15M | $33 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 19, 2026, we had a total of 31 employees, 30 of whom were full-time.”
Corporate history
Events identified from SEC filings